Kreatech Announces BioMicro to Distribute its Product Line in North America
News Aug 02, 2007
Kreatech Biotechnology BV and BioMicro® Systems Inc. announced a partnership whereby BioMicro Systems will distribute the Kreatech ULS™ solutions for microarrays to laboratories in the United States and Canada.
The partnership will strengthen the focus of Kreatech and its labeling solutions offerings towards microarray use to North American life science investigators and service providers, and secure easy access to the non-enzymatic nucleic acid labeling solutions.
The Kreatech Universal Linkage System (ULS) allows for the attachment of a variety of labels directly to DNA, RNA and proteins. These products are centered on a proprietary platinum-based system that produces highly stable labeling under a wide variety of conditions. The ULS products are available with a wide variety of industry standard dyes, offering a versatile solution for the labeling of protein, RNA and DNA in microarray applications.
“This agreement expands our reach into the North American microarray user base through a focused and experienced microfluidic and microarray technology solution provider,” said Rik van Heijningen, Kreatech Biotechnology Vice President of Commercial Operations. “We look forward to working with BioMicro Systems and expanding our array labeling user network”.
“Based on the success of the MAUI® System product line, BioMicro Systems wants to broaden its product offerings to offer additional breakthrough microarray products,” said Michael Feldman, Ph.D., Chief Executive Officer of BioMicro Systems. “Through partnering with Kreatech, BioMicro Systems will offer the best microarray labeling kits to U.S. and Canadian researchers.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.